Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Childhood Central Nervous System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Nervous System Neoplasm
Central Nervous System Neoplasm
Childhood Central Nervous System Neoplasm

Subtype

Childhood Central Nervous System Neoplasm

CI-CAN-00000694Explore in graph →

PediatricNon-malignant51 active trials24 evidence items

NCIt: C5132

Overview
Statistics
Survival
Genomics
Variants & evidence24
Drugs8
Trials217
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (15)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–15 of 15 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
· Nat Med · 2024 · PMID 37978284 · validated civic_curation pubmed
Pediatric low-grade gliomas can be molecularly stratified for risk.
· Acta Neuropathol · 2018 · PMID 29948154 · validated civic_curation pubmed
BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma.
· Clin Cancer Res · 2011 · PMID 21610142 · validated civic_curation pubmed
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.
· Nat Genet · 2013 · PMID 23583981 · validated civic_curation pubmed
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
· Cell Cycle · 2006 · PMID 17172831 · validated civic_curation pubmed
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.
· Cancer Cell · 2015 · PMID 25965575 · validated civic_curation pubmed
Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features.
· Brain Pathol · 2019 · PMID 30246434 · validated civic_curation

Showing 1–15 of 15 publications

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

· Lancet Oncol · 2019 · PMID 31151904 · validated civic_curation pubmed

Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.

· J Pathol · 2009 · PMID 19197950 · validated civic_curation pubmed

Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.

· J Clin Oncol · 2010 · PMID 20713864 · validated civic_curation pubmed

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.

· J Transl Med · 2014 · PMID 25524464 · validated civic_curation pubmed

Supratentorial ependymoma with YAP1:FAM118B fusion: A case report.

· Neuropathology · 2021 · PMID 33480048 · validated civic_curation pubmed

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

· Oncotarget · 2017 · PMID 28002790 · validated civic_curation pubmed

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.

· Oncotarget · 2017 · PMID 29156677 · validated civic_curation pubmed